Torren Management
NRIX icon

Torren Management’s Nurix Therapeutics NRIX Stock Holding History

Torren Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.4K Hold
59
– – ﹤0.01% 643
2026
Q2 		$1.43K Hold
59
– – ﹤0.01% 661
2026
Q1 		$915 Hold
59
– – ﹤0.01% 756
2025
Q4 		$1.12K Buy
+59
New +$848 ﹤0.01% 1178

Other funds holding NRIX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Torren Management's NRIX Position: Q3 2026 in Review

Torren Management held its Nurix Therapeutics (NRIX) position steady in Q3 2026 at 59 shares worth $1.4K. The position accounts for ﹤0.01% of the portfolio, ranked #643.

Torren Management first reported a position in NRIX in Q4 2025 and has held it in 4 quarters since. The position peaked at $1.43K in Q2 2026. 68 funds tracked by Wall St. Rank hold NRIX as of Q3 2026.

  • Torren Management held 59 shares of Nurix Therapeutics worth $1.4K as of Q3 2026.
  • Torren Management left its Nurix Therapeutics share count unchanged in Q3 2026.
  • Nurix Therapeutics made up ﹤0.01% of Torren Management's portfolio in Q3 2026, its #643 holding.
  • Torren Management first reported a position in Nurix Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • Torren Management's Nurix Therapeutics position peaked at $1.43K in Q2 2026.
  • 68 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2026.

Based on Torren Management's 13F filing for Q3 2026, filed 29 Oct 2026.